Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH

Watchlist Manager
Reviva Pharmaceuticals Holdings, Inc. Logo
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Watchlist
Price: 1.815 USD 1.97%
Market Cap: 60.7m USD
Have any thoughts about
Reviva Pharmaceuticals Holdings, Inc.?
Write Note

Reviva Pharmaceuticals Holdings, Inc.
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Reviva Pharmaceuticals Holdings, Inc.
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Other Current Assets
$1.3m
CAGR 3-Years
46%
CAGR 5-Years
99%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Current Assets
$4.2B
CAGR 3-Years
5%
CAGR 5-Years
12%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Assets
$1.8B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-2%
Pfizer Inc
NYSE:PFE
Other Current Assets
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
-9%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Other Current Assets
$7.4B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Other Current Assets
$8.4B
CAGR 3-Years
40%
CAGR 5-Years
29%
CAGR 10-Years
26%
No Stocks Found

Reviva Pharmaceuticals Holdings, Inc.
Glance View

Market Cap
60.7m USD
Industry
Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.

RVPH Intrinsic Value
2.415 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Reviva Pharmaceuticals Holdings, Inc.'s Other Current Assets?
Other Current Assets
1.3m USD

Based on the financial report for Sep 30, 2024, Reviva Pharmaceuticals Holdings, Inc.'s Other Current Assets amounts to 1.3m USD.

What is Reviva Pharmaceuticals Holdings, Inc.'s Other Current Assets growth rate?
Other Current Assets CAGR 5Y
99%

Over the last year, the Other Current Assets growth was 202%. The average annual Other Current Assets growth rates for Reviva Pharmaceuticals Holdings, Inc. have been 46% over the past three years , 99% over the past five years .

Back to Top